Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandutinib in Recurrent Glioblastoma
NCT00379080Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tandutinib in glioblastoma (GBM), sponsored by National Cancer Institute. Started Jan 2007; status: completed.
02
Drugs
tandutinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00379080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379080.